Human VEGF165 Protein, premium grade
分子别名(Synonym)
RP1-261G23.1,MGC70609,MVCD1,VEGFA,VPF
表达区间及表达系统(Source)
Human VEGF165, premium grade (VE5-H4210) is expressed from human 293 cells (HEK293). It contains AA Ala 27 - Arg 191 (Accession # P15692-4).
Predicted N-terminus: Ala 27
该产品是在我们严格的质量控制体系下生产的,该体系包括一系列全面的测试,包括无菌和内毒素测试。在临床前早期阶段,产品性能经过仔细验证和测试,可用于细胞培养或任何其他应用。当准备进入后期临床阶段时,我们还提供定制GMP蛋白质服务,以满足您的需求。我们将与您合作,根据您的要求定制和开发GMP级产品,该产品也符合细胞疗法细胞制造中使用的原材料和辅助材料的要求。
蛋白结构(Molecular Characterization)
![1.jpg 1.jpg](/SupplyImg1/2024-07-03/6385561492319567256801964.jpg)
This protein carries no "tag".
The protein has a calculated MW of 19.2 kDa. The protein migrates as 24 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
内毒素(Endotoxin)
Less than 0.01 EU per μg by the LAL method.
宿主蛋白残留(Host Cell Protein)
<0.5 ng/µg of protein tested by ELISA.
宿主核酸残留(Host Cell DNA)
<0.02 ng/μg of protein tested by qPCR.
无菌(Sterility)
Negative
支原体(Mycoplasma)
Negative.
纯度(Purity)
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
制剂(Formulation)
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
重构方法(Reconstitution)
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
存储(Storage)
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 24 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
![2.jpg 2.jpg](/SupplyImg1/2024-07-03/6385561493101148684088576.jpg)
![3.jpg 3.jpg](/SupplyImg1/2024-07-03/6385561493367358331137190.jpg)
![4.jpg 4.jpg](/SupplyImg1/2024-07-03/6385561493633053458749910.jpg)
![5.jpg 5.jpg](/SupplyImg1/2024-07-03/6385561493896145275451862.jpg)
背景(Background)
VEGF165是VEGF-A最丰富的剪接变体。VEGF165由许多细胞产生,包括内皮细胞,巨噬细胞和T细胞。VEGF165参与血管生成,血管内皮细胞存活,生长,迁移和血管通透性。VEGF基因表达由缺氧,炎性细胞因子和癌基因诱导。VEGF165与硫酸乙酰肝素结合并保留在细胞表面和细胞外基质中。VEGF165与受体酪氨酸激酶VEGFR1和VEGFR2结合。VEGF165是唯一与共受体NRP-1和NRP-2结合的剪接变体,其功能是增强VEGFR2信号传导。VEGF165与VEGFR1和VEGFR2的结合导致PI3K/AKT,p38 MAPK,FAK和桩蛋白的激活。VEGF在许多癌症的肿瘤血管生成中起关键作用。
关键字: VEGF165;VEGF165蛋白;VEGF165重组蛋白;ACRO;百普赛斯;
百普赛斯集团ACROBiosystems Group(股票代码:301080)是成立于2010年的跨国生物科技公司,是为全球生物医药、健康产业领域提供关键生物试剂产品及解决方案的行业平台型基石企业。2021年在创业板上市。百普赛斯集团业务遍布全球,横跨亚洲、北美洲、欧洲,在中国、美国、瑞士等12个城市设有办公室、研发中心及生产基地。目前累计服务客户超6000家,与全球Top 20医药企业均建立了长期、稳定的合作伙伴关系。集团旗下拥有品牌ACROBiosystems百普赛斯、bioSeedin柏思荟、Condense Capital垦拓资本和ACRODiagnostics百斯医学等。